Chinese acceptance of zanidatamab filing

11 June 2024
zymeworks-large

The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidatamab for second-line treatment of HER2-positive biliary tract cancer (BTC).

This is good news for Zymeworks (Nasdaq: ZYME), a Canadian biotech that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. Shares in the company were more than 2% higher early in Tuesday morning's trading in New York.

Zanidatamab is a bispecific antibody developed using Zymeworks’ proprietary Azymetric platform that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. It is being advanced in multiple cancer types in partnership with US biopharma Jazz Pharmaceuticals (Nasdaq: JAZZ) and Sino-American biotech BeiGene (Nasdaq: BGNE).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology